Cargando…

Dengue-specific subviral nanoparticles: design, creation and characterization

BACKGROUND: Dengue is today the most significant of arboviral diseases. Novel tools are necessary to effectively address the problem of dengue. Virus-like particles (VLP) offer a versatile nanoscale platform for developing tools with potential biomedical applications. From the perspective of a poten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khetarpal, Niyati, Poddar, Ankur, Nemani, Satish K, Dhar, Nisha, Patil, Aravind, Negi, Priyanka, Perween, Ashiya, Viswanathan, Ramaswamy, Lünsdorf, Heinrich, Tyagi, Poornima, Raut, Rajendra, Arora, Upasana, Jain, Swatantra K, Rinas, Ursula, Swaminathan, Sathyamangalam, Khanna, Navin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680219/ https://www.ncbi.nlm.nih.gov/pubmed/23706089 http://dx.doi.org/10.1186/1477-3155-11-15

Ejemplares similares

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
por: Arora, Upasana, et al.
Publicado: (2012)

Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of Hepatitis B surface antigen
por: Gurramkonda, Chandrasekhar, et al.
Publicado: (2009)

A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice
por: Ramasamy, Viswanathan, et al.
Publicado: (2018)

Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies
por: Tripathi, Lav, et al.
Publicado: (2015)

Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera
por: Batra, Gaurav, et al.
Publicado: (2011)

Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies
por: Poddar, Ankur, et al.
Publicado: (2016)

A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture
por: Raut, Rajendra, et al.
Publicado: (2015)

Pichia pastoris-Expressed Dengue 2 Envelope Forms Virus-Like Particles without Pre-Membrane Protein and Induces High Titer Neutralizing Antibodies
por: Mani, Shailendra, et al.
Publicado: (2013)

Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo
por: Shukla, Rahul, et al.
Publicado: (2018)

Subviral Agents
por: STRAUSS, JAMES H., et al.
Publicado: (2008)

Dengue envelope-based ‘four-in-one’ virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice
por: Rajpoot, Ravi Kant, et al.
Publicado: (2018)

Virus-like particle production with yeast: ultrastructural and immunocytochemical insights into Pichia pastoris producing high levels of the Hepatitis B surface antigen
por: Lünsdorf, Heinrich, et al.
Publicado: (2011)

Subviral particle as vaccine and vaccine platform
por: Tan, Ming, et al.
Publicado: (2014)

Escherichia coli–expressed near full length HIV-1 envelope glycoprotein is a highly sensitive and specific diagnostic antigen
por: Talha, Sheikh M, et al.
Publicado: (2012)

Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin
por: Gurramkonda, Chandrasekhar, et al.
Publicado: (2010)

Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement
por: Shukla, Rahul, et al.
Publicado: (2020)

Physiological response of Pichia pastoris GS115 to methanol-induced high level production of the Hepatitis B surface antigen: catabolic adaptation, stress responses, and autophagic processes
por: Vanz, Ana Leticia, et al.
Publicado: (2012)

An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes
por: Khanam, Saima, et al.
Publicado: (2007)

The Fittest versus the Flattest: Experimental Confirmation of the Quasispecies Effect with Subviral Pathogens
por: Codoñer, Francisco M, et al.
Publicado: (2006)

An Attenuated Strain of Human Cytomegalovirus for the Establishment of a Subviral Particle Vaccine
por: Krauter, Steffi, et al.
Publicado: (2022)

Adenovirus Delivered Short Hairpin RNA Targeting a Conserved Site in the 5′ Non-Translated Region Inhibits All Four Serotypes of Dengue Viruses
por: Korrapati, Anil Babu, et al.
Publicado: (2012)

Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms
por: Ho, Joan Kha-Tu, et al.
Publicado: (2020)

Cissampelos pareira Linn: Natural Source of Potent Antiviral Activity against All Four Dengue Virus Serotypes
por: Sood, Ruchi, et al.
Publicado: (2015)

Fate of the UPR marker protein Kar2/Bip and autophagic processes in fed-batch cultures of secretory insulin precursor producing Pichia pastoris
por: Roth, Gustavo, et al.
Publicado: (2018)

Subviral Dense Bodies of Human Cytomegalovirus Induce an Antiviral Type I Interferon Response
por: Penner, Inessa, et al.
Publicado: (2022)

Dengue Fever: Causes, Complications, and Vaccine Strategies
por: Khetarpal, Niyati, et al.
Publicado: (2016)

The Subviral RNA Database: a toolbox for viroids, the hepatitis delta virus and satellite RNAs research
por: Rocheleau, Lynda, et al.
Publicado: (2006)

Activation of ERAD Pathway by Human Hepatitis B Virus Modulates Viral and Subviral Particle Production
por: Lazar, Catalin, et al.
Publicado: (2012)

Characterization Of The Interaction Between Subviral Particles Of Hepatitis B Virus And Dendritic Cells – In Vitro Study
por: Farag, Mohamed MS, et al.
Publicado: (2019)

Production Strategies for Pentamer-Positive Subviral Dense Bodies as a Safe Human Cytomegalovirus Vaccine
por: Gogesch, Patricia, et al.
Publicado: (2019)

Incorporation of apolipoprotein E into HBV–HCV subviral envelope particles to improve the hepatitis vaccine strategy
por: Gomez-Escobar, Elsa, et al.
Publicado: (2021)

Proteome changes of fibroblasts and endothelial cells upon incubation with human cytomegalovirus subviral Dense Bodies
por: Penner, Inessa, et al.
Publicado: (2023)

Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain
por: Tabata, Koshiro, et al.
Publicado: (2023)

Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models
por: Shukla, Rahul, et al.
Publicado: (2020)

Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles
por: Artpradit, Charlermchai, et al.
Publicado: (2013)

Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus
por: Harahap-Carrillo, Indira S., et al.
Publicado: (2015)

Development of a highly specific serodiagnostic ELISA for West Nile virus infection using subviral particles
por: Maezono, Keisuke, et al.
Publicado: (2021)

Cryo-EM structures of human hepatitis B and woodchuck hepatitis virus small spherical subviral particles
por: Liu, Haitao, et al.
Publicado: (2022)

Simultaneous detection of Human Immunodeficiency Virus 1 and Hepatitis B virus infections using a dual-label time-resolved fluorometric assay
por: Myyryläinen, Tiina, et al.
Publicado: (2010)

Subviral Dense Bodies of Human Cytomegalovirus Enhance Interferon-Beta Responses in Infected Cells and Impair Progeny Production
por: Penner, Inessa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_igh3auap5p4sqke879skk67hb7